Arena Stock Falls On Unusually High Volume (ARNA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Arena Pharmaceuticals (Nasdaq: ARNA) is trading at unusually high volume Friday with 18.5 million shares changing hands. It is currently at two times its average daily volume and trading down 64 cents (-6.2%) at $9.80 as of 3:51 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Arena has a market cap of $2.27 billion and is part of the health care sector and drugs industry. Shares are up 15.9% year to date as of the close of trading on Thursday.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

TheStreet Ratings rates Arena as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth. You can view the full Arena Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case